Advance Your Genomic Research Using Targeted Resequencing with SeqCap EZ Library
|
|
- Harvey Patrick
- 6 years ago
- Views:
Transcription
1 Advance Your Genomic Research Using Targeted Resequencing with SeqCap EZ Library Marilou Wijdicks International Product Manager Research For Life Science Research Only. Not for Use in Diagnostic Procedures.
2 Why Perform Targeted Resequencing? Focus Your Research on Relevant Regions Genetic Diseases: identify mutations that correlate to disease or contribute to genetic risk. Follow up of GWAS, re-sequence of disease associated regions Exome sequencing for discovery of mutations in rare diseases Candidate genes panels involved in disease pathways Cancer: identify somatic mutations involved in tumorigenesis or metastasis, discover germ line mutations that contribute to cancer risk. Focus on exome or cancer gene panel for comprehensive coverage of known and rare mutations Deep sequencing of cancer related regions to identify rare mutations present in heterogeneous tumor tissues
3 Exome Capture Comparison Study - Stanford Sept 25, 2011 Study compared the performance of three capture technologies: NimbleGen SeqCap EZ Exome Library v2.0 Agilent SureSelect Exome Illumina TruSeq Exome Comparison of single nucleotide variant (SNV) detection between exome and whole genome sequencing Clark et al., Performance comparison of exome DNA sequencing technologies (2011) Nature Biotechnology Published online 25 September 2011 doi:1038/nbt
4 Exome Capture Comparison Study - Stanford Efficiency and Coverage Percentage bases covered with >10X coverage with 80M reads NimbleGen 96.8% Agilent 89.6% Illumina 90.0% NimbleGen SeqCap EZ Exome demonstrate(s) the highest efficiency target enrichment, able to adequately cover the largest proportion of its targeted bases with the least amount of sequencing. Clark et al., Performance comparison of exome DNA sequencing technologies (2011) Nature Biotechnology Published online 25 September 2011 doi:1038/nbt
5 Exome Capture Comparison Study - Stanford Indel Detection b. Indels detected in bases targeted c. Indels detected in RefSeq coding region In shared and RefSeq regions, NimbleGen had the highest sensitivity for detecting indels because of higher average read depth. Clark et al., Performance comparison of exome DNA sequencing technologies (2011) Nature Biotechnology Published online 25 September 2011 doi:1038/nbt
6 Exome Capture Comparison Study - Stanford Comparison to Whole Genome Sequencing we found that exome sequencing can identify variants that are not evident in WGS (Whole Genome Sequencing) because of greater base coverage after enrichment. Clark et al., Performance comparison of exome DNA sequencing technologies (2011) Nature Biotechnology Published online 25 September 2011 doi:1038/nbt
7 Exome Capture Comparison Study BGI Sept 28, 2011 Study compared the performance of three capture technologies: NimbleGen SeqCap EZ Exome Library v1.0 NimbleGen Sequence Capture 2.1M Array Agilent SureSelect Exome the NimbleGen platforms showed better uniformity of coverage and greater genotype sensitivity at folds sequencing depth. Asan et al., Comprehensive comparison of three commercial human whole-exome capture platforms (2011) Genome Biology Published online 28 September 2011, 12:R95
8 Exome Capture Comparison Study FINN Sept 28, 2011 Study compared the performance of two capture technologies: NimbleGen SeqCap EZ Exome Library v2.0 Agilent SureSelect Exome In our data, libraries captured with NimbleGen kits aligned more accurately to the target regions. NimbleGen SeqCap v2.0 most efficiently covered the exome with a minimum coverage of 20x... Sulonen et al., Comparison of solution-based exome capture methods for next generation sequencing (2011) Genome Biology Published online 28 September 2011, 12:R94
9 NimbleGen SeqCap EZ Products From small custom gene panel to Exome Unique design process with up to 2.1 million long DNA probes to ensure high target coverage and good capture uniformity. Optimized protocols for Illumina and Roche 454 Sequencing systems SeqCap EZ Choice Library Capture any regions from 100kb 50Mb. Available in convenient kit sizes: 12, 24, 48, 96, 384, and 960 reactions. SeqCap EZ Exome v2.0 Library Superior coverage due to empirical rebalancing Targeting 44 Mb human genomic regions, covering coding exons from ~ 20K unique genes from RefSeq and CCDS, and 710 mirna genes.
10 NimbleGen SeqCap EZ Exome Products New 64Mb Exome Unique design process with up to 2.1 million long DNA probes to ensure high target coverage and good capture uniformity. Optimized protocols for Illumina and Roche 454 Sequencing systems SeqCap EZ Exome Library v2.0 Superior coverage due to empirical rebalancing Targeting 44 Mb human genomic regions, covering coding exons from ~ 20K unique genes from RefSeq and CCDS, and 710 mirna genes. SeqCap EZ Exome Library v3.0 New! Superior coverage due to empirical rebalancing Targeting 64 Mb human genomic regions, covering coding exons from ~ 20K unique genes from RefSeq, CCDS, Ensembl, Vega, Gencode, and mirbase.
11 SeqCap EZ Workflow Capture any targets from 100kb 50Mb with 2.1 million long oligos in solution Target Regions Prepare with Next-Gen Sequencing Adaptors SeqCap EZ (Solution Capture) Amplify DNA and Enrichment QC Sequence DNA on a Next-Gen Sequencer Genomic DNA Library Preparation Hybridization Capture and Washing Amplification and QC Sequencing
12 SeqCap EZ Choice Probe Design More Probes, Better Capture Simple Tiling Design (Agilent) Target Region Up to 55,000 (120mer) probes/baits tiled across the region. NimbleGen Sequence Capture Design Target Region Up to 2,100,000 (50-105mer) probes selected for the region using special algorithm. Significantly more probes, 38X. Benefits: Higher density tiling Redundancy to reduce risk Ability to move probes for better uniformity
13 NimbleGen SeqCap EZ Library Reduce Sequencing Costs Capture Uniformity Good depth Average depth Poor depth $ Exon 1 Exon 2 Exon 3 Minimum data required
14 NimbleGen SeqCap EZ Library Reduce Sequencing Costs Capture Uniformity Good depth Average depth Poor depth $ $ Exon 1 Exon 2 Exon 3 Minimum data required
15 NimbleGen SeqCap EZ Library Reduce Sequencing Costs Capture Uniformity Good depth Average depth Poor depth $ $ $ Exon 1 Exon 2 Exon 3 Minimum data required
16 NimbleGen SeqCap EZ Exome Products New 64Mb Exome Unique design process with up to 2.1 million long DNA probes to ensure high target coverage and good capture uniformity. Optimized protocols for Illumina and Roche 454 Sequencing systems SeqCap EZ Exome Library v2.0 Superior coverage due to empirical rebalancing Targeting 44 Mb human genomic regions, covering coding exons from ~ 20K unique genes from RefSeq and CCDS, and 710 mirna genes. SeqCap EZ Exome Library v3.0 New! Superior coverage due to empirical rebalancing Targeting 64 Mb human genomic regions, covering coding exons from ~ 20K unique genes from RefSeq, CCDS, Ensembl, Vega, Gencode, and mirbase.
17 NimbleGen SeqCap EZ Exome Library v3 Achieve the most comprehensive coverage of coding regions % 98.00% 96.00% 94.00% 92.00% 90.00% 88.00% RefSeq Vega Gencode Ensembl CCDS mirbase SeqCap EZ Exome v3 SureSelect TruSeq
18 Coverage of Coding Exons How does SeqCap EZ Exome Library v3.0 compare? Gigabases of input sequence
19 Coverage of raw sequence How does SeqCap EZ Exome v3.0 compare?
20 Multiplex SeqCap EZ Illumina TruSeq Library ADAPTERS library prep (pre-cap multiplexing) capture INDEXE D INDEXE D (post-cap multiplexing) sequencing (GAIIx or HiSeq2000)
21 Precap Multiplexing with Illumina TruSeq Libraries Balanced distribution of indexed reads Million Read 8 Samples (4 tumor/normal pairs) Each capture reaction was sequenced with 1 lane on HiSeq (2x100bp pairedend)
22 SeqCap EZ Exome Pre Capture Multiplexing Experimental Summary Pre Capture vs. Post Capture Multiplexing Yoruban Trio captured with both 3 plex pre capture and 3 plex post capture Pre and post capture multiplex sequenced on separate Illumina HiSeq lanes 2x100 bp Exome 7 plex Pre Capture Multiplexing 3 Exome captures with 7 samples pre captured in each capture Each replicate sequenced on one Illumina HiSeq lane 2x100 bp Protocols for use with Illumina TruSeq Libraries Preparation Kit can be found at nimblegen.com
23 SeqCap EZ Exome Pre Capture Multiplexing Balanced index reads distribution compared to post capture NA19238, postcap NA19239, postcap NA19240, postcap NA19238, precap NA19239, precap NA19240, precap One Lane of HiSeq v3 sequenced at 100 bp reads and subsampled to 75 Million Reads
24 SeqCap EZ Exome Pre Capture Multiplexing Post Capture - 3 samples Pre Capture 3 samples % On Target ~72% ~71% Average Coverage ~50x ~46x Median Coverage ~40x ~38x % bases at > 10 coverage ~93% ~93% % PCR Duplicates ~1% ~2.5% % Sensitivity ~97% ~97% % Specificity ~99% ~99% One Lane of HiSeq v3 sequenced at 100 bp reads and subsampled to 75 Million Reads
25 SeqCap EZ Exome Pre Capture Multiplexing Balanced distribution of indexed reads raw reads NA19238 NA19239 NA19240 One Lane of HiSeq v3 sequenced at 100 bp reads and raw reads/not subsampled
26 SeqCap EZ Exome Pre Capture Multiplexing Av. raw reads 7 plex pre capture on 3 separate HiSeq lanes Pre Capture (ave 7 plex) Pre Capture (ave 7 plex) Pre Capture (ave 7 plex) One Lane of HiSeq v3 sequenced at 100bp reads and raw reads/not subsampled
27 SeqCap EZ Exome Pre Capture Multiplexing Pre Capture 3 samples Pre Capture - 7 samples % On Target ~71% ~72% Average Coverage ~75x ~33x Median Coverage ~60x ~26x % bases at > 10 coverage ~95% ~87% % PCR Duplicates ~4% ~2.5% % Sensitivity ~98% ~93% % Specificity ~99% ~98% One Lane of HiSeq v3 sequenced at 100 bp reads and raw reads/not subsampled
28 Percent coverage SeqCap EZ Exome Pre Capture Multiplexing Coverage depth Coverage depth for 3 plex pre capture multiplexing and one lane of Illumina HiSeq
29 Automated SeqCap EZ Workflow Using the Caliper Sciclone NGS Workstation Optimized scripts written for the SeqCap EZ workflow Capability to load tips as needed based on number of samples 24 deck locations for more walk-away time Small size to fit on bench top Fully enclosed system for contamination protection Process 288 samples per week
30 NimbleGen SeqCap EZ Exome v.2.0 Automation vs. Manual Chr 22 Sequence Coverage from Automated Protocol on Sciclone Sequence Coverage from Manual Protocol Target Exons HapMap sample NA12762 was captured with either automated protocol or manual protocol with NimbleGen SeqCap EZ Exome v2.0.
31 IMPORTANT NOTICE Intended Use Unless explicitly stated otherwise, all Roche NimbleGen products and services referenced in this presentation are intended for the following use: For Life Science Research Only. Not for Use in Diagnostic Procedures. 454, 454 SEQUENCING, GS JUNIOR, NIMBLEGEN and SEQCAP are trademarks of Roche. All other product names and trademarks are the property of their respective owners 2011 Roche NimbleGen, Inc.
32 We Innovate Healthcare
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect
More informationMultiplex target enrichment using DNA indexing for ultra-high throughput variant detection
Multiplex target enrichment using DNA indexing for ultra-high throughput variant detection Dr Elaine Kenny Neuropsychiatric Genetics Research Group Institute of Molecular Medicine Trinity College Dublin
More informationUsing the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep
Using the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep Tom Walsh, PhD Division of Medical Genetics University of Washington Next generation sequencing Sanger sequencing gold
More informationAVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB
Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits Next-generation performance in liquid biopsies 2 Accelerating clinical research From liquid biopsy to next-generation
More informationInvestigating rare diseases with Agilent NGS solutions
Investigating rare diseases with Agilent NGS solutions Chitra Kotwaliwale, Ph.D. 1 Rare diseases affect 350 million people worldwide 7,000 rare diseases 80% are genetic 60 million affected in the US, Europe
More informationBack to the Basics: Methyl-Seq 101
Back to the Basics: Methyl-Seq 101 Presented By: Alex Siebold, Ph.D. October 9, 2013 Field Applications Scientist Agilent Technologies Life Sciences & Diagnostics Group Life Sciences & Diagnostics Group
More informationCytogenetics 101: Clinical Research and Molecular Genetic Technologies
Cytogenetics 101: Clinical Research and Molecular Genetic Technologies Topics for Today s Presentation 1 Classical vs Molecular Cytogenetics 2 What acgh? 3 What is FISH? 4 What is NGS? 5 How can these
More informationSCALPEL MICRO-ASSEMBLY APPROACH TO DETECT INDELS WITHIN EXOME-CAPTURE DATA. Giuseppe Narzisi, PhD Schatz Lab
SCALPEL MICRO-ASSEMBLY APPROACH TO DETECT INDELS WITHIN EXOME-CAPTURE DATA Giuseppe Narzisi, PhD Schatz Lab November 14, 2013 Micro-Assembly Approach to detect INDELs 2 Outline Scalpel micro-assembly pipeline
More informationNGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation
NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation Michael R. Rossi, PhD, FACMG Assistant Professor Division of Cancer Biology, Department of Radiation Oncology Department
More informationPerformance Characteristics BRCA MASTR Plus Dx
Performance Characteristics BRCA MASTR Plus Dx with drmid Dx for Illumina NGS systems Manufacturer Multiplicom N.V. Galileïlaan 18 2845 Niel Belgium Table of Contents 1. Workflow... 4 2. Performance Characteristics
More informationDNA-seq Bioinformatics Analysis: Copy Number Variation
DNA-seq Bioinformatics Analysis: Copy Number Variation Elodie Girard elodie.girard@curie.fr U900 institut Curie, INSERM, Mines ParisTech, PSL Research University Paris, France NGS Applications 5C HiC DNA-seq
More informationIdentifying Mutations Responsible for Rare Disorders Using New Technologies
Identifying Mutations Responsible for Rare Disorders Using New Technologies Jacek Majewski, Department of Human Genetics, McGill University, Montreal, QC Canada Mendelian Diseases Clear mode of inheritance
More informationSmall RNA Sequencing. Project Workflow. Service Description. Sequencing Service Specification BGISEQ-500 SERVICE OVERVIEW SAMPLE PREPARATION
BGISEQ-500 SERVICE OVERVIEW Small RNA Sequencing Service Description Small RNAs are a type of non-coding RNA (ncrna) molecules that are less than 200nt in length. They are often involved in gene silencing
More informationPerformance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffinembedded lung adenocarcinoma samples
Bonfiglio et al. BMC Cancer (2016) 16:692 DOI 10.1186/s12885-016-2720-4 RESEARCH ARTICLE Open Access Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffinembedded
More informationAnalysis with SureCall 2.1
Analysis with SureCall 2.1 Danielle Fletcher Field Application Scientist July 2014 1 Stages of NGS Analysis Primary analysis, base calling Control Software FASTQ file reads + quality 2 Stages of NGS Analysis
More informationMutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research
Mutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research Application Note Authors John McGuigan, Megan Manion,
More informationA complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis
APPLICATION NOTE Cell-Free DNA Isolation Kit A complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis Abstract Circulating cell-free DNA (cfdna) has been shown
More informationFONS Nové sekvenační technologie vklinickédiagnostice?
FONS 2010 Nové sekvenační technologie vklinickédiagnostice? Sekvenování amplikonů Sequence capture Celogenomové sekvenování FONS 2010 Sekvenování amplikonů Amplicon sequencing - amplicon sequencing enables
More informationAbstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction
Optimization strategy of Copy Number Variant calling using Multiplicom solutions Michael Vyverman, PhD; Laura Standaert, PhD and Wouter Bossuyt, PhD Abstract Copy number variations (CNVs) represent a significant
More informationCRISPR/Cas9 Enrichment and Long-read WGS for Structural Variant Discovery
CRISPR/Cas9 Enrichment and Long-read WGS for Structural Variant Discovery PacBio CoLab Session October 20, 2017 For Research Use Only. Not for use in diagnostics procedures. Copyright 2017 by Pacific Biosciences
More informationHigh Throughput TruSeq Stranded mrna Library Construction on the Biomek FX P
High Throughput TruSeq Stranded mrna Library Construction on the Biomek FX P Zach Smith and Scott D. Michaels The Center for Genomics and Bioinformatics Indiana University Bloomington, IN USA Mary Blair
More informationAnalysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers
Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers Gordon Blackshields Senior Bioinformatician Source BioScience 1 To Cancer Genetics Studies
More informationACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics
ACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics Precision Genomics for Immuno-Oncology Personalis, Inc. ACE ImmunoID When one biomarker doesn t tell the whole
More informationSomatic cancer applications of NGS in in vitro Diagnostics.
Somatic cancer applications of NGS in in vitro Diagnostics. Nitin Udar PhD In Vitro Diagnsotics Division Illumina, Inc. 2013 Illumina, Inc. All rights reserved. Illumina, IlluminaDx, BaseSpace, BeadArray,
More informationCharacterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser
Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why
More informationIlluminating the genetics of complex human diseases
Illuminating the genetics of complex human diseases Michael Schatz Sept 27, 2012 Beyond the Genome @mike_schatz / #BTG2012 Outline 1. De novo mutations in human diseases 1. Autism Spectrum Disorder 2.
More informationFluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS
APPLICATION NOTE Fluxion Biosciences and Swift Biosciences OVERVIEW This application note describes a robust method for detecting somatic mutations from liquid biopsy samples by combining circulating tumor
More informationEvaluation of MIA FORA NGS HLA test and software. Lisa Creary, PhD Department of Pathology Stanford Blood Center Research & Development Group
Evaluation of MIA FORA NGS HLA test and software Lisa Creary, PhD Department of Pathology Stanford Blood Center Research & Development Group Disclosure Alpha and Beta Studies Sirona Genomics Reagents,
More information2/10/2016. Evaluation of MIA FORA NGS HLA test and software. Disclosure. NGS-HLA typing requirements for the Stanford Blood Center
Evaluation of MIA FORA NGS HLA test and software Lisa Creary, PhD Department of Pathology Stanford Blood Center Research & Development Group Disclosure Alpha and Beta Studies Sirona Genomics Reagents,
More informationFrequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R
Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB
More informationSimple, rapid, and reliable RNA sequencing
Simple, rapid, and reliable RNA sequencing RNA sequencing applications RNA sequencing provides fundamental insights into how genomes are organized and regulated, giving us valuable information about the
More informationNGS in tissue and liquid biopsy
NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences
More informationTOWARDS ACCURATE GERMLINE AND SOMATIC INDEL DISCOVERY WITH MICRO-ASSEMBLY. Giuseppe Narzisi, PhD Bioinformatics Scientist
TOWARDS ACCURATE GERMLINE AND SOMATIC INDEL DISCOVERY WITH MICRO-ASSEMBLY Giuseppe Narzisi, PhD Bioinformatics Scientist July 29, 2014 Micro-Assembly Approach to detect INDELs 2 Outline 1 Detecting INDELs:
More informationncounter Data Analysis Guidelines for Copy Number Variation (CNV) Molecules That Count NanoString Technologies, Inc.
ncounter Data Analysis Guidelines for Copy Number Variation (CNV) NanoString Technologies, Inc. 530 Fairview Ave N Suite 2000 Seattle, Washington 98109 www.nanostring.com Tel: 206.378.6266 888.358.6266
More informationIso-Seq Method Updates and Target Enrichment Without Amplification for SMRT Sequencing
Iso-Seq Method Updates and Target Enrichment Without Amplification for SMRT Sequencing PacBio Americas User Group Meeting Sample Prep Workshop June.27.2017 Tyson Clark, Ph.D. For Research Use Only. Not
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AD Award Number: W81XWH-10-1-0589 TITLE: Global Characterization of Protein Altering Mutations in Prostate Cancer PRINCIPAL INVESTIGATOR: Jay Shendure, M.D., Ph.D. CONTRACTING ORGANIZATION: University
More informationCancer Gene Panels. Dr. Andreas Scherer. Dr. Andreas Scherer President and CEO Golden Helix, Inc. Twitter: andreasscherer
Cancer Gene Panels Dr. Andreas Scherer Dr. Andreas Scherer President and CEO Golden Helix, Inc. scherer@goldenhelix.com Twitter: andreasscherer About Golden Helix - Founded in 1998 - Main outside investor:
More informationP. Tang ( 鄧致剛 ); PJ Huang ( 黄栢榕 ) g( ); g ( ) Bioinformatics Center, Chang Gung University.
Databases and Tools for High Throughput Sequencing Analysis P. Tang ( 鄧致剛 ); PJ Huang ( 黄栢榕 ) g( ); g ( ) Bioinformatics Center, Chang Gung University. HTseq Platforms Applications on Biomedical Sciences
More informationIdentification of genomic alterations in cervical cancer biopsies by exome sequencing
Chapter- 4 Identification of genomic alterations in cervical cancer biopsies by exome sequencing 105 4.1 INTRODUCTION Athough HPV has been identified as the prime etiological factor for cervical cancer,
More informationNo mutations were identified.
Hereditary High Cholesterol Test ORDERING PHYSICIAN PRIMARY CONTACT SPECIMEN Report date: Aug 1, 2017 Dr. Jenny Jones Sample Medical Group 123 Main St. Sample, CA Kelly Peters Sample Medical Group 123
More informationBreast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS
Breast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS dr sc. Ana Krivokuća Laboratory for molecular genetics Institute for Oncology and
More informationSingle-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA
www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2016 Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) DNA Supplementary Materials
More informationGenomic structural variation
Genomic structural variation Mario Cáceres The new genomic variation DNA sequence differs across individuals much more than researchers had suspected through structural changes A huge amount of structural
More informationMEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG)
Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Ordering Information Acceptable specimen types: Fresh blood sample (3-6 ml EDTA; no time limitations associated with receipt)
More informationAccel-Amplicon Panels
Accel-Amplicon Panels Amplicon sequencing has emerged as a reliable, cost-effective method for ultra-deep targeted sequencing. This highly adaptable approach is especially applicable for in-depth interrogation
More informationCirculating Cell-Free DNA Pre-analytics: Importance of ccfdna Stabilization and Extraction for Liquid Biopsy Applications
Circulating Cell-Free DNA Pre-analytics: Importance of ccfdna Stabilization and Extraction for Liquid Biopsy Applications Martin Schlumpberger, Ass.Director R&D, QIAGEN GmbH IQNpath 2017 - Circulating
More informationSupplementary Figure 1
Supplementary Figure 1 Supplementary Fig. 1: Quality assessment of formalin-fixed paraffin-embedded (FFPE)-derived DNA and nuclei. (a) Multiplex PCR analysis of unrepaired and repaired bulk FFPE gdna from
More informationSureSelect Cancer All-In-One Custom and Catalog NGS Assays
SureSelect Cancer All-In-One Custom and Catalog NGS Assays Detect all cancer-relevant variants in a single SureSelect assay SNV Indel TL SNV Indel TL Single DNA input Single AIO assay Single data analysis
More informationSelective depletion of abundant RNAs to enable transcriptome analysis of lowinput and highly-degraded RNA from FFPE breast cancer samples
DNA CLONING DNA AMPLIFICATION & PCR EPIGENETICS RNA ANALYSIS Selective depletion of abundant RNAs to enable transcriptome analysis of lowinput and highly-degraded RNA from FFPE breast cancer samples LIBRARY
More informationAD (Leave blank) TITLE: Genomic Characterization of Brain Metastasis in Non-Small Cell Lung Cancer Patients
AD (Leave blank) Award Number: W81XWH-12-1-0444 TITLE: Genomic Characterization of Brain Metastasis in Non-Small Cell Lung Cancer Patients PRINCIPAL INVESTIGATOR: Mark A. Watson, MD PhD CONTRACTING ORGANIZATION:
More informationImportance of Cell Stock Concentration for Accurate Target Cell Recovery
TECHNICAL NOTE Importance of Cell Stock Concentration for Accurate Target Cell Recovery INTRODUCTION 10x Genomics Single Cell Protocols require suspensions of viable, single cells (Single Cell Protocols
More informationSynthetic microrna Reference Standards Genomics Research Group ABRF 2015
Synthetic microrna Reference Standards Genomics Research Group ABRF 2015 Don A. Baldwin, Ph.D. support@signalbiology.com Reference samples for Platform evaluation Protocol development Assay service improvement
More informationPlease Silence Your Cell Phones. Thank You
Please Silence Your Cell Phones Thank You Utility of NGS and Comprehensive Genomic Profiling in Hematopathology Practice Maria E. Arcila M.D. Memorial Sloan Kettering Cancer Center New York, NY Disclosure
More informationThe Importance of Coverage Uniformity Over On-Target Rate for Efficient Targeted NGS
WHITE PAPER The Importance of Coverage Uniformity Over On-Target Rate for Efficient Targeted NGS Yehudit Hasin-Brumshtein, Ph.D., Maria Celeste M. Ramirez, Ph.D., Leonardo Arbiza, Ph.D., Ramsey Zeitoun,
More informationNext Generation Sequencing as a tool for breakpoint analysis in rearrangements of the globin-gene clusters
Next Generation Sequencing as a tool for breakpoint analysis in rearrangements of the globin-gene clusters XXXth International Symposium on Technical Innovations in Laboratory Hematology Honolulu, Hawaii
More informationCentoXome FUTURE'S KNOWLEDGE APPLIED TODAY
CentoXome FUTURE'S KNOWLEDGE APPLIED TODAY More genetic information requires cutting-edge interpretation techniques Whole Exome Sequencing For certain patients the combination of symptoms does not allow
More informationLiquid biopsy in lung cancer: The EGFR paradigm
Liquid biopsy in lung cancer: The EGFR paradigm Lynette M. Sholl, M.D. Brigham and Women s Hospital Dana Farber Cancer Institute Department of Pathology Boston, MA Disclosure of Relevant Financial Relationships
More informationCentoXome FUTURE'S KNOWLEDGE APPLIED TODAY
CentoXome FUTURE'S KNOWLEDGE APPLIED TODAY More genetic information requires cutting-edge interpretation techniques Whole Exome Sequencing For some patients, the combination of symptoms does not allow
More informationMolecular Characterization of Tumors Using Next-Generation Sequencing
Molecular Characterization of Tumors Using Next-Generation Sequencing Using BaseSpace to visualize molecular changes in cancer. Tumor-Normal Sequencing Data in BaseSpace To enable researchers new to next-generation
More informationSupplementary Figure 1. Schematic diagram of o2n-seq. Double-stranded DNA was sheared, end-repaired, and underwent A-tailing by standard protocols.
Supplementary Figure 1. Schematic diagram of o2n-seq. Double-stranded DNA was sheared, end-repaired, and underwent A-tailing by standard protocols. A-tailed DNA was ligated to T-tailed dutp adapters, circularized
More informationVARIANT PRIORIZATION AND ANALYSIS INCORPORATING PROBLEMATIC REGIONS OF THE GENOME ANIL PATWARDHAN
VARIANT PRIORIZATION AND ANALYSIS INCORPORATING PROBLEMATIC REGIONS OF THE GENOME ANIL PATWARDHAN Email: apatwardhan@personalis.com MICHAEL CLARK Email: michael.clark@personalis.com ALEX MORGAN Email:
More informationACE ImmunoID. ACE ImmunoID. Precision immunogenomics. Precision Genomics for Immuno-Oncology
ACE ImmunoID ACE ImmunoID Precision immunogenomics Precision Genomics for Immuno-Oncology Personalis, Inc. A universal biomarker platform for immuno-oncology Patient response to cancer immunotherapies
More informationCNV detection. Introduction and detection in NGS data. G. Demidov 1,2. NGSchool2016. Centre for Genomic Regulation. CNV detection. G.
Introduction and detection in NGS data 1,2 1 Genomic and Epigenomic Variation in Disease group, Centre for Genomic Regulation 2 Universitat Pompeu Fabra NGSchool2016 methods: methods Outline methods: methods
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature11396 A total of 2078 samples from a large sequencing project at decode were used in this study, 219 samples from 78 trios with two grandchildren who were not also members of other trios,
More informationAgilent s Copy Number Variation (CNV) Portfolio
Technical Overview Agilent s Copy Number Variation (CNV) Portfolio Abstract Copy Number Variation (CNV) is now recognized as a prevalent form of structural variation in the genome contributing to human
More informationncounter TM Analysis System
ncounter TM Analysis System Molecules That Count TM www.nanostring.com Agenda NanoString Technologies History Introduction to the ncounter Analysis System CodeSet Design and Assay Principals System Performance
More informationAssessing Laboratory Performance for Next Generation Sequencing Based Detection of Germline Variants through Proficiency Testing
Assessing Laboratory Performance for Next Generation Sequencing Based Detection of Germline Variants through Proficiency Testing Karl V. Voelkerding, MD Professor of Pathology University of Utah Medical
More informationMYC Translocations In Multiple Myeloma Involve Recruitment Of Enhancer Elements Resulting In Over- Expression and Decreased Overall Survival
in partnership with MYC Translocations In Multiple Myeloma Involve Recruitment Of Enhancer Elements Resulting In Over- Expression and Decreased Overall Survival Brian A Walker Centre for Myeloma Research,
More informationImplementation of the DDD/ClinGen OGT (CytoSure v3) Microarray
Implementation of the DDD/ClinGen OGT (CytoSure v3) Microarray OGT UGM Birmingham 08/09/2016 Dom McMullan Birmingham Women's NHS Trust WM chromosomal microarray (CMA) testing Population of ~6 million (10%)
More informationGolden Helix s End-to-End Solution for Clinical Labs
Golden Helix s End-to-End Solution for Clinical Labs Steven Hystad - Field Application Scientist Nathan Fortier Senior Software Engineer 20 most promising Biotech Technology Providers Top 10 Analytics
More informationEnabling Personalized
Molecular Enabling Personalized Diagnostics Medicine- Targeted Sequencing: NGS-based solutions Silvia Dorn Roel Reinders- Andreas Diplas Friday, 19.06.2015 Company Overview Founded in April 2011 Development
More informationCalling DNA variants SNVs, CNVs, and SVs. Steve Laurie Variant Effect Predictor Training Course Prague, 6 th November 2017
1 Calling DNA variants SNVs, CNVs, and SVs Steve Laurie Variant Effect Predictor Training Course Prague, 6 th November 2017 Calling DNA variants SNVs, CNVs, SVs 2 1. What is a variant? 2. Paired End read
More informationNEXT GENERATION SEQUENCING. R. Piazza (MD, PhD) Dept. of Medicine and Surgery, University of Milano-Bicocca
NEXT GENERATION SEQUENCING R. Piazza (MD, PhD) Dept. of Medicine and Surgery, University of Milano-Bicocca SANGER SEQUENCING 5 3 3 5 + Capillary Electrophoresis DNA NEXT GENERATION SEQUENCING SOLEXA-ILLUMINA
More informationSeptember 23, The Role of In Vitro Diagnostic Tests in Pediatric Master Protocol Development
The Role of In Vitro Diagnostic Tests in Pediatric Master Protocol Development September 23, 2016 Anand Pathak, MD, PhD, MPH Medical Officer Molecular Genetics Branch Division of Molecular Genetics and
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature13908 Supplementary Tables Supplementary Table 1: Families in this study (.xlsx) All families included in the study are listed. For each family, we show: the genders of the probands and
More informationThe feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients
The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients ASSC Scientific Meeting 13 th October 2016 Prof Andrew Barbour UQ SOM
More informationIntroduction of an NGS gene panel into the Haemato-Oncology MPN service
Introduction of an NGS gene panel into the Haemato-Oncology MPN service Dr. Anna Skowronska, Dr Jane Bryon, Dr Samuel Clokie, Dr Yvonne Wallis and Professor Mike Griffiths West Midlands Regional Genetics
More informationLynch Syndrome and COLARIS Testing
Lynch Syndrome and COLARIS Testing Webinar Objectives Review of Lynch syndrome as a multi-gene disorder COLARIS Enhancements Technical Overview COLARIS test offerings Test development and validation process
More informationEnterprise Interest Thermo Fisher Scientific / Employee
Enterprise Interest Thermo Fisher Scientific / Employee A next-generation sequencing assay to estimate tumor mutation load from FFPE research samples Fiona Hyland. Director of R&D, Bioinformatics Clinical
More information!"##"$%#"&!'&$'()$(%&'*& Terapia Pediatrica e Farmacologia dello Sviluppo +,-./&01,23&34,53& :&;.<&2-.=;:3&;.;2>6-6&-.&;&
!!! "#$%&'($)*!+&,-$!.)/+$!+$!01,-$1'$!!"##"$%#"&!'&$'()$(%&'*& Terapia Pediatrica e Farmacologia dello Sviluppo 0$2-3!44566!! +,-./&01,23&34,53&63783.9-.:&;.6-6&-.&;& 582/-:3.3?;/-,.;2&@;5-2>&63:?3:;/-.:&#>A3&B&!-;C3/36&!.&))3'&!(2$&#)$7$23!+$(2$8-$#1'&!+$!177&'[!!
More informationSupplementary Tables. Supplementary Figures
Supplementary Files for Zehir, Benayed et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients Supplementary Tables Supplementary Table 1: Sample
More informationVictor Guryev. European Research Institute for the Biology of Ageing
Victor Guryev European Research Institute for the Biology of Ageing September 29, 2014 Genomic resequencing in Medical diagnostics course Erasmus MC, Rotterdam /a /g Low coverage whole genome and deep
More informationMEDICAL GENOMICS LABORATORY. Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG)
Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG) Ordering Information Acceptable specimen types: Blood (3-6ml EDTA; no time limitations associated with receipt) Saliva (OGR-575 DNA Genotek;
More informationWhole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute
Whole Genome and Transcriptome Analysis of Anaplastic Meningioma Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Outline Anaplastic meningioma compared to other cancers Whole genomes
More informationCNV Detection and Interpretation in Genomic Data
CNV Detection and Interpretation in Genomic Data Benjamin W. Darbro, M.D., Ph.D. Assistant Professor of Pediatrics Director of the Shivanand R. Patil Cytogenetics and Molecular Laboratory Overview What
More informationPERSONALIZED GENETIC REPORT CLIENT-REPORTED DATA PURPOSE OF THE X-SCREEN TEST
INCLUDED IN THIS REPORT: REVIEW OF YOUR GENETIC INFORMATION RELEVANT TO ENDOMETRIOSIS PERSONAL EDUCATIONAL INFORMATION RELEVANT TO YOUR GENES INFORMATION FOR OBTAINING YOUR ENTIRE X-SCREEN DATA FILE PERSONALIZED
More informationIntroduction to LOH and Allele Specific Copy Number User Forum
Introduction to LOH and Allele Specific Copy Number User Forum Jonathan Gerstenhaber Introduction to LOH and ASCN User Forum Contents 1. Loss of heterozygosity Analysis procedure Types of baselines 2.
More informationGenomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationPersonalis ACE Clinical Exome The First Test to Combine an Enhanced Clinical Exome with Genome- Scale Structural Variant Detection
Personalis ACE Clinical Exome The First Test to Combine an Enhanced Clinical Exome with Genome- Scale Structural Variant Detection Personalis, Inc. 1350 Willow Road, Suite 202, Menlo Park, California 94025
More informationScreening for novel oncology biomarker panels using both DNA and protein microarrays. John Anson, PhD VP Biomarker Discovery
Screening for novel oncology biomarker panels using both DNA and protein microarrays John Anson, PhD VP Biomarker Discovery Outline of presentation Introduction to OGT and our approach to biomarker studies
More informationBWA alignment to reference transcriptome and genome. Convert transcriptome mappings back to genome space
Whole genome sequencing Whole exome sequencing BWA alignment to reference transcriptome and genome Convert transcriptome mappings back to genome space genomes Filter on MQ, distance, Cigar string Annotate
More informationOptimizing Copy Number Variation Analysis Using Genome-wide Short Sequence Oligonucleotide Arrays
Optimizing Copy Number Variation Analysis Using Genome-wide Short Sequence Oligonucleotide Arrays The Harvard community has made this article openly available. Please share how this access benefits you.
More informationAssessing intercomponent. heterogeneity of biphasic uterine carcinosarcoma. December 7, 2018
December 7, 2018 Assessing intercomponent heterogeneity of biphasic uterine carcinosarcoma Research Grand Rounds 2018 Avera McKennan Hospital Presented by Erik Ehli, PhD Research Grand Rounds Brief Outline:
More informationHome Brewed Personalized Genomics
Home Brewed Personalized Genomics The Quest for Meaningful Analysis Results of a 23andMe Exome Pilot Trio of Myself, Wife, and Son February 22, 2013 Gabe Rudy, Vice President of Product Development Exome
More informationDr Rick Tearle Senior Applications Specialist, EMEA Complete Genomics Complete Genomics, Inc.
Dr Rick Tearle Senior Applications Specialist, EMEA Complete Genomics Topics Overview of Data Processing Pipeline Overview of Data Files 2 DNA Nano-Ball (DNB) Read Structure Genome : acgtacatgcattcacacatgcttagctatctctcgccag
More informationAndrew Parrish, Richard Caswell, Garan Jones, Christopher M. Watson, Laura A. Crinnion 3,4, Sian Ellard 1,2
METHOD ARTICLE An enhanced method for targeted next generation sequencing copy number variant detection using ExomeDepth [version 1; referees: 1 approved, 1 approved with reservations] 1 2 1 3,4 Andrew
More informationChIP-seq data analysis
ChIP-seq data analysis Harri Lähdesmäki Department of Computer Science Aalto University November 24, 2017 Contents Background ChIP-seq protocol ChIP-seq data analysis Transcriptional regulation Transcriptional
More informationValidation of copy number variation analysis for next-generation sequencing diagnostics
(2017) 25, 719 724 & 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 1018-4813/17 $32.00 www.nature.com/ejhg ARTICLE Validation of copy number variation analysis for next-generation
More informationPlatform Approach to Cancer Discovery and Diagnostics Development
Platform Approach to Cancer Discovery and Diagnostics Development Joanne Yeakley Staff Manager, Scientific Research Diagnostic Assay Development 2009 Illumina, Inc. All rights reserved. Illumina, illuminadx,
More informationComprehensive Analyses of Circulating Cell- Free Tumor DNA
Comprehensive Analyses of Circulating Cell- Free Tumor DNA Boston, MA June 28th, 2016 Derek Murphy, Ph.D. Scientist, Research and Development Personal Genome Diagnostics Acquisition of Somatic Alterations
More information